[Rifaximin in the treatment of hepatic encephalopathy].
Hepatic encephalopathy is a frequent and serious complication of liver cirrhosis. Usually it is treated by non-absorbable disaccharides or antibiotics and its treatment is often difficult and associated with undesirable effects. The objective of our investigation was to evaluate the safety and effectiveness of a new antibiotic used in this indication--rifaximine. With rifaximine, 400 mg three times per day, a total of 25 patients were treated for a 10-day period. Significant improvement of the manifestations of encephalopathy occurred (evaluated by the grade of encephalopathy, test of combining numerals, the degree of flapping tremor and the arterial ammonia level). None of the patients developed undesirable effects. Rifaximine seems an effective, safe drug for hepatic encephalopathy.
Lata
J
J
Interní gastroenterologická klinika FN Brno.
Hůlek
P
P
Fejfar
T
T
Spicák
J
J
Drastich
P
P
Marecek
Z
Z
Brůha
R
R
Husová
L
L
Senkyrík
M
M
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
D000890:Anti-Infective Agents; D012294:Rifamycins; D000078262:Rifaximin